Drugs to prevent and reverse anticoagulation

Anesthesiology Clinics of North America

Volumn 17, Issue 4, 1999, Pages 799-811

  Franck, M ^a   Sladen, R N ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; FIBRINOGEN; HEPARIN; HEPARIN LYASE; HEXADIMETHRINE BROMIDE; ILOPROST; PLASMIN; PLASMINOGEN; PROSTACYCLIN; PROTAMINE; TRANEXAMIC ACID;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; DIABETES INSIPIDUS; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG OVERDOSE; FIBRINOLYSIS; HUMAN; HYPOTENSION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032710293     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(05)70134-6     Document Type: Article

References (46)

1. T. Ammar C.F. Fisher The effects of heparinase 1 and protamine on platelet reactivity Anesthesiology 86 1997 1382
2. L. Andersson I.M. Nilsson S. Colleen Role or urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA Ann NY Acad Sci 146 1968 642
3. R.E. Ariano B. Seymour Inverse relationship between desmopressin dosage and antidiuresis Clin Pharm 10 1991 912
4. D.G. Bichet M. Razi M. Lonergan 1-Desamino (8-D arginine) vasopressin (dDAVP) decreases blood pressure and increases pulse rate in normal individuals Thromb Haemost 60 1988 348
5. B.S. Bull W.M. Huse F.S. Brauer Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage J Thorac Cardiovasc Surg 69 1975 785
6. C. Canavese M. Salomone A. Pacitti Reduced response of uraemic bleeding time to repeated doses of desmopressin Lancet 1 1985 867
7. W.E. Cobb S. Spare S. Reichlin Neurogenic diabetes insipidus: Management with DDAVP(r) (1-Desamino-8-D Arginine Vasopressin) Ann Intern Med 88 1978 183
8. F.S. D'Alauro R.A. Johns Hypotension related to desmopressin administration following cardiopulmonary bypass Anesthesiology 69 1988 962
9. M.N. D'Ambra S.C. Risk Aprotinin, erythropoietin and blood substitutes Int Anesthesiol Clin 28 1990 237
10. G.J. Despotis J.H. Joist C.W.J. Hogue The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation J Thorac Cardiovasc Surg 110 1995 46
11. H. Fodstad A. Forssell B. Liliequist Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: A consecutive controlled clinical trial Neurosurgery 8 1981 158
12. D.D. Frankville G.B. Harper C.L. Lake Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass Anesthesiology 74 1991 988
13. S.K. Gupta F.J. Veith E. Ascer Anaphylactoid reactions to protamine: An often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery J Vasc Surg 9 1988 342
14. J.F. Hardy J. Desroches Natural and synthetic antifibrinolytics in cardiac surgery Can J Anaesth 73 1994 395
15. L. Holmberg I.M. Nilsson L. Borge Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease N Engl J Med 309 1983 816
16. J.C. Horrow Desmopressin and antifibrinolytics Int Anesthesiol Clin 28 1990 230
17. J.C. Horrow Protamine: A review of its toxicity Anesth Analg 64 1985 348
18. M. Hoylaerts H.R. Lijnen D. Colien Studies on the mechanism of antifibrinolytic action of tranexamic acid Biochim Biophys Acta 673 1981 75
19. M. Kikura M.K. Lee J.H. Levy Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass Anesth Analg 83 1996 223
20. S.N. Konstadt Protamine administration: Untoward responses and their mechanisms Mt Sinai J Med 54 1987 297
21. H.C. Kwaan T. Astrup Tissue repair in presence of locally applied inhibitors of fibrinolysis Exp Mol Pathol 11 1969 82
22. J.H. Levy J.M. Bailey M. Salmenpera Pharmacokinetics of aprotinin in preoperative cardiac surgical patients Anesthesiology 80 1994 1013
23. P.W. Majerus G.J. Broze J.P. Miletich Anticoagulants, thrombolytic, and antiplatelet drugs Hardman J.G. Limbird L.E. Molinoff P.B. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996 McGraw-Hill New York 1341 1360
24. P.M. Mannucci J.M. Lusher Desmopressin and thrombosis [letter] Lancet 2 1989 675
25. P.M. Mannucci Hemostatic drugs N Engl J Med 339 1998 245
26. L.G. Michelsen M. Kikura J.H. Levy Heparinase I (neutralase) reversal of systemic anticoagulation Anesthesiology 85 1996 339
27. B. Milne K. Rogers F. Cervenko The haemodynamic effects of intraaortic versus intravenous administration of protamine for reversal of heparin in man Can Anaesth Soc J 30 1983 347
28. T. Mochizuki P.J. Olson F. Szlam Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass Anesth Analg 87 1998 781
29. D.R. Morel W.M. Zapol S.J. Thomas C5 and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin Anesthesiology 66 1987 597
30. A. Ordonez Fernandez A. Hernandez Fernandez J.M. Borrego Dominguez The systemic vasodilatory action of protamine: Is it inhibited or mediated by heparin? Res Exp Med (Berl) 197 1998 337
31. L.A. Pagliaro L.Z. Benet Pharmacokinetic Data J Pharmacokinet Biopharm 3 1975 333
32. A.L. Pauca J.E. Graham A.S. Hudspeth Hemodynamic effects of intraaortic administration of protamine Ann Thorac Surg 35 1983 637
33. A. Perkash A comparison of the quantitative action of protamine and heparin on blood coagulation: Significance in clinical and laboratory usage Am J Clin Pathol 73 1980 767
34. E. Puigdellivol M.E. Carral J. Moreno Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man Int J Clin Pharmacol Ther Toxicol 23 1985 298
35. R.A. Rizza S. Sclonick C.L. Conley Myoglobinuria following aminocaproic acid administration JAMA 236 1976 1845
36. A.G. Robinson DDAVP(r) in the treatment of central diabetes insipidus N Engl J Med 294 1976 507
37. K.M. Salva H.C. Kim K. Nahum DDAVP in the treatment of bleeding disorders Pharmacotherapy 8 1988 94
38. E.W. Salzman M.J. Weinstein R.M. Weintraub Treatment with desmopressin acetate to reduce blood loss after cardiac surgery N Engl J Med 314 1986 1402
39. S.M. Seif T.V. Zenser F.F. Ciarochi DDAVP® (1-Desamino-8-Arginine Vasopressin) treatment of central diabetes insipidus: Mechanism of prolonged antidiuresis J Clin Endocrinol Metab 46 1978 381
40. J.N. Shanberge M. Murato T. Quattrociocchi-Longe Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures Am J Clin Pathol 87 1987 210
41. L. Shore-Lesserson D.L. Reich M. DePerio Heparin and protamine titration do not improve haemostasis in cardiac surgical patients Can J Anaesth 45 1998 10
42. C. Swartz G. Onesti O. Ramirez Cardiac and renal hemodynamic effects of the antifibrinolytic agents, epsilon aminocaproic acid Curr Ther Res 8 1966 336
43. W. Tao D.J. Deyo R.L.J. Brunston Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass ASAIO J 43 1997 M825
44. M. Verstraete Clinical application of inhibitors of fibrinolysis Drugs 29 1985 236
45. J.M. Weiler P. Freiman M.D. Sharath Serious adverse reactions to protamine sulfate: Are alternatives needed? J Allergy Clin Immunol 75 1985 297
46. J.R. Zaidan S. Johnson R. Brynes Rate of protamine administration: Its effect on heparin reversal and antithrombin recovery after coronary artery surgery Anesth Analg 65 1986 377